⌘K
t
On 13 August 2025, Solvonis Therapeutics plc noted the publication of an article on ThisIsMoney.co.uk (Daily Mail online). The article, titled "SMALL CAP IDEA: Ketamine drip therapy firm is taking on alcoholism", highlighted Solvonis' recent acquisition of Awakn Life Sciences and the integration of its development pipeline. It also referenced the Company's lead programme, SVN-001, in Phase III clinical trials for severe AUD in the UK and EU, and SVN-002 targeting the US AUD market.
| Date | 13 Aug 2025 |
| Time | 15:03:11 |
| Category | Miscellaneous |
| ID | 2234V |
("Solvonis" or the "Company")
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, notes the publication of an article on ThisIsMoney.co.uk (Daily Mail online) titled "SMALL CAP IDEA: Ketamine drip therapy firm is taking on alcoholism".
The article, written by Ian Lyall of Proactive Investors, highlights:
· Solvonis' recent acquisition of Awakn Life Sciences and the integration of its development pipeline.
· The Company's lead programme, SVN-001, in Phase III clinical trials for severe AUD for the UK and EU AUD markets, combining ketamine infusion with Cognitive Behavioural Therapy (CBT).
· The Company's second programme, SVN-002, targeting the US AUD market via the FDA's 505(b)(2) regulatory pathway, referencing Johnson & Johnson's approved esketamine product Spravato®.
· Sector valuation comparisons with US-listed peers and recent M&A activity highlighting strategic interest in novel mental health therapeutics.
· The full article can be accessed here:
https://www.thisismoney.co.uk/money/markets/article-14996499/SMALL-CAP-IDEA-Ketamine-drip-therapy-firm-taking-alcoholism.html
Enquiries:
Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
anthony@solvonis.com
Allenby Capital Limited (Financial Adviser and Joint Broker)
Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)
Guy McDougall (Sales & Corporate Broking)
+44 (0) 20 3328 5656
Singer Capital Markets (Joint Broker)
Phil Davies
+44 (0) 20 7496 3000
About Solvonis Therapeutics plc
Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.
The Company's lead programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD programme leveraging novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.
In addition, Solvonis is advancing an AI-supported discovery platform built on a proprietary CNS compound library, with initial focus on depression and stimulant use disorders. This initiative expands the Company's R&D pipeline into earlier-stage innovation while maintaining strategic focus on comorbid and underserved neuropsychiatric conditions.
With a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to generate value through innovation in neuropsychiatry.
solvonis.com | LinkedIn | X (Twitter)